# Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

> **NCT01225913** · PHASE4 · RECRUITING · sponsor: **Gelb, Arthur F., M.D.** · enrollment: 50 (estimated)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** fluticasone/salmeterol in all asthmatics
- **DRUG:** budesonide/formoterol or fluticasone/salmeterol in all asthmatics

## Key facts

- **NCT ID:** NCT01225913
- **Lead sponsor:** Gelb, Arthur F., M.D.
- **Sponsor class:** INDIV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2007-10
- **Primary completion:** 2027-06
- **Final completion:** 2027-06
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01225913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01225913, "Mechanism(s) of Airflow Limitation During Exacerbation of Asthma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01225913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*